Full reference for the long-acting IGF-1 analog — mechanism, evidence, strict 4–6 week cycle rationale, hypoglycemia safety protocol, and COA-verified pricing.
Research context only. IGF-1 LR3 carries significant hypoglycemia risk. Glucose monitoring required. Not medical advice.
Natural IGF-1 is produced primarily in the liver in response to GH stimulation. It circulates bound to IGF binding proteins (IGFBPs) — which act as a reservoir and regulator, keeping most IGF-1 inactive until needed. Free (unbound) IGF-1 is the active fraction; the IGFBPs prevent immediate receptor saturation and control IGF-1's half-life.
IGF-1 LR3's arginine substitution at position 3 and N-terminal extension dramatically reduce IGFBP binding affinity. The result: nearly all injected IGF-1 LR3 circulates in free, active form. This bypasses the body's IGFBP regulatory system entirely, producing sustained IGF-1R activation for 20–30 hours rather than the minutes provided by natural pulses.
The regulatory bypass concern: The IGFBP system exists for good reasons — it prevents runaway IGF-1 signaling, maintains tissue specificity, and prevents hypoglycemia. IGF-1 LR3's near-complete bypass of this system produces stronger anabolic effects but also removes important safeguards. This is why hypoglycemia risk and short cycle lengths are non-negotiable research parameters.
| Application | Evidence Level | Key Findings |
|---|---|---|
| Muscle hypertrophy | Strong (animal) | Clear dose-dependent muscle mass increases; satellite cell activation confirmed |
| Protein synthesis | Strong (mechanistic + animal) | mTOR/PI3K/Akt pathway activation well-characterized |
| Recovery / repair | Moderate (animal) | Faster muscle damage recovery, reduced atrophy in immobilization models |
| Human anabolic effects | Observational | Extensive community use data; no formal Phase 2/3 trials |
| Cancer promotion | Theoretical + epidemiological | IGF-1R activation linked to cancer in population studies; direct IGF-1 LR3 data limited |
| Parameter | Value | Notes |
|---|---|---|
| Dose | 20–60 mcg/day | Start at 20mcg; increase only with glucose monitoring in place |
| Timing | Post-workout with food | Never fasted; food present reduces hypoglycemia risk |
| Cycle | 4–6 weeks maximum | Receptor downregulation and cumulative risk make longer cycles counterproductive |
| Off period | Equal to cycle length | 4–6 weeks off to restore receptor sensitivity |
| Glucose monitoring | Required | Check before injection; have fast carbs available |
COA-verified vendor pricing with promo codes and reconstitution guide.
View Pricing → Dosage Calculator